Safety multifly 20 gx3 4 tw needle

Whole blood was collected by venipuncture (Safety-Multifly^® 20 Gx3/4 TW needle; Sarstedt, Nümbrecht, Germany) in heparin- (19 I.U./mL, Sarstedt, Germany) or EDTA- containing monovettes (EDTA-K 1.6 mg/mL, Sarstedt, Germany) after donors were informed and gave their written informed consent. The blood of four healthy donors was pooled for each procedure. The blood pooling was carried out according to specific instructions in the European Pharmacopoiea (EP) [17 ]. The strict exclusion criteria for blood donors of the EP also applied: no non-steroidal anti-inflammatory drugs (e.g., ibuprofen) at least 48 h before blood sampling and no steroidal anti-inflammatory drugs 7 days prior to blood sampling. The blood collection procedures were approved by the research and ethics unit of the University of Tübingen (project approval number 287/2020BO2).

Blood was obtained from five voluntary healthy adults by venipuncture (Safety-Multifly^® 20 Gx3/4 TW needle; Sarstedt, Nümbrecht, Germany) after giving their informed consent. To enable conclusive in vitro blood experiments, relatively low anticoagulation with 1 IU/mL sodium heparin 25,000 (Ratiopharm, Ulm, Germany) was used. To guarantee the quality of the blood, strict exclusion criteria were applied to blood donors: e.g., smoking and medication were prohibited. In particular, the intake of drugs inhibiting coagulation and inflammation in the last two weeks before blood donation was not allowed. The blood collection procedures described and the use of blood in the experimental settings were approved by the Research and Ethics Department of the University of Tuebingen (project approval number 287/2020BO2).